Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;112(1):89-96.
doi: 10.17269/s41997-020-00332-3. Epub 2020 Jun 11.

Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018)

Darrell H S Tan  1   2   3   4 , Thomas M Dashwood  5 , James Wilton  6 , Abigail Kroch  6 , Tara Gomes  7   8 , Diana Martins  7
Affiliations

Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015-2018)

Darrell H S Tan et al. Can J Public Health. 2021 Feb.

Abstract
in English, French

Objectives: HIV pre-exposure prophylaxis (PrEP) is a proven tool for HIV prevention, but PrEP use in Ontario, Canada, and the effects of recent policies are unknown. We estimated the number and characteristics of PrEP users in Ontario and evaluated the impacts of policy changes between July 2015 and June 2018.

Methods: We obtained tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) dispensation data for Ontario from IQVIA, and applied an algorithm to identify use for PrEP. We report prevalent PrEP use for the second quarter of 2018 according to age, sex, region, prescriber specialty, and payer type, and generate "PrEP-to-need ratios" (PNR) by dividing these numbers by the estimated numbers of new HIV diagnoses. We used interventional autoregressive integrated moving average models to examine the impact of three policy changes on PrEP use: Health Canada approval (February 2016), availability of generic TDF/FTC and partial public drug coverage (September 2017), and public drug coverage for individuals aged < 25 years (January 2018).

Results: The estimated number of individuals receiving PrEP increased 713%, from 374 in 2015 Q3 to 3041 in 2018 Q2. Among PrEP users in 2018 Q2, 97.5% were male, 60.4% were < 40 years, 67.7% obtained PrEP from a family physician, 77.2% used private insurance, and 67.0% were in Toronto. PNRs were highest in 30-39-year-olds, males, Toronto and the Central East and West regions. Time series analyses found that Health Canada approval (p = 0.0001) and introducing generics/partial public drug coverage (p = 0.002) led to significantly increased use.

Conclusions: PrEP use has risen in Ontario in association with favourable policy changes, but remains far below guideline recommendations.

RéSUMé: OBJECTIFS: La prophylaxie pré-exposition (PPrE) est un outil éprouvé pour prévenir le VIH, mais le recours à la PPrE en Ontario (Canada) et les effets de politiques récentes sont inconnus. Nous avons estimé le nombre et les caractéristiques des utilisateurs de la PPrE en Ontario et évalué les incidences de changements de politique survenus entre juillet 2015 et juin 2018. MéTHODE: Nous avons obtenu auprès d’IQVIA des données sur l’administration de fumarate de ténofovir disoproxil (FTD) et d’emtricitabine (FTC) en Ontario et appliqué un algorithme pour déterminer le recours à la PPrE. Nous présentons la prévalence du recours à la PPrE au deuxième trimestre de 2018 selon l’âge, le sexe, la région, la spécialité du médecin prescripteur et le type de payeur, et nous générons des « ratios PPrE-besoins » (RPB) en divisant ces nombres par les nombres estimatifs de nouveaux diagnostics de VIH. Nous avons utilisé des modèles interventionnels fondés sur la moyenne mobile intégrée autorégressive pour examiner les incidences de trois changements de politique sur le recours à la PPrE : l’approbation par Santé Canada (février 2016); la disponibilité de versions génériques du FTD et de la FTC et leur couverture partielle par le régime public d’assurance-médicaments (septembre 2017); et la couverture des moins de 25 ans par le régime public d’assurance-médicaments (janvier 2018). RéSULTATS: Le nombre estimatif de personnes recevant la PPrE a augmenté de 713 %, passant de 374 au troisième trimestre de 2015 à 3041 au deuxième trimestre de 2018. Chez les utilisateurs de la PPrE au deuxième trimestre de 2018, 97,5 % étaient des hommes, 60,4 % avaient moins de 40 ans, 67,7 % obtenaient la PPrE auprès d’un médecin de famille, 77,2 % utilisaient une assurance privée, et 67,0 % vivaient à Toronto. Les RPB les plus élevés ont été observés chez les 30 à 39 ans, chez les hommes et chez les résidents de Toronto et des régions du Centre-Est et du Centre-Ouest. Selon les résultats d’analyses des séries chronologiques, l’approbation par Santé Canada (p = 0,0001) et l’introduction de versions génériques/la couverture partielle par le régime public d’assurance-médicaments (p = 0,002) ont entraîné des hausses significatives du recours à la PPrE. CONCLUSIONS: Le recours à la PPrE a augmenté en Ontario en lien avec des changements de politique favorables, mais il demeure très en-deçà des recommandations des lignes directrices.

Keywords: HIV; Policy; Pre-exposure prophylaxis; Prevention and control; Public health.

PubMed Disclaimer

Conflict of interest statement

In the past 3 years, DHST’s institution has received research support for investigator-initiated research studies from Gilead Sciences and Viiv Healthcare, outside the submitted work. DHST is a Site Principal Investigator for clinical trials sponsored by Glaxo Smith Kline, outside the submitted work.

Figures

Fig. 1
Fig. 1
TDF/FTC dispensations and inferred clinical indications, April 2018–June 2018. Estimated number of individuals dispensed TDF/FTC in Ontario during 2018 Q2, classified by clinical indication. TDF/FTC = tenofovir disoproxil fumarate and emtricitabine
Fig. 2
Fig. 2
PrEP-to-need ratio by geographic region in Ontario. Ratio calculated using 2018 Q2 PrEP data and 2017 new HIV diagnosis data. 1 = North West, 2 = North East, 3 = Ottawa, 4 = Eastern, 5 = Central East, 6 = Durham, 7 = York, 8 = Toronto, 9 = Peel, 10 = Halton, 11 = Central South, 12 = Central West, 13 = South West, 14 = Erie-St.Clair. Regions based on (aggregations of) Public Health Unit (PHU) boundaries (see Table S2). Maps created using Statistics Canada boundary files (Statistics Canada 2015)
Fig. 3
Fig. 3
Estimated number of PrEP users over time in Ontario by sex (a), among females (b), by age (c), and among individuals aged < 25 years (d) and intervention time series analysis. Estimates were obtained using an autoregressive integrated moving average model, with intervention time series analysis of Health Canada approval of PrEP (February 2016), introduction of generic and ODB coverage (September 2017), and introduction of OHIP+ (January 2018). A ramp intervention function was used to test for gradual changes in trends and a step intervention function was used to test for immediate changes, based on visual inspection of the time series. Estimates were based on the monthly number of individuals using PrEP in Ontario between 2015 Q3 and 2018 Q2. PrEP = pre-exposure prophylaxis. ODB = Ontario Drug Benefit. OHIP+ = Ontario Health Insurance Plan Plus
See this image and copyright information in PMC

References

    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine. 2012;367(5):399–410. doi: 10.1056/NEJMoa1108524. - DOI - PMC - PubMed
    1. Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP awareness and perceived barriers among single young men who have sex with men in the United States. Current HIV Research. 2013;11(7):520–527. doi: 10.2174/1570162X12666140129100411. - DOI - PMC - PubMed
    1. Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., et al. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England), 381(9883), 2083–2090 10.1016/S0140-6736(13)61127-7. - PubMed
    1. Dearing J, Kee K. Historical roots of dissemination and implementation science. In: Brownson RC, Colditz GA, Proctor EK, editors. Dissemination and implementation research in health. New York: Oxford University Press; 2012.
    1. Dinh, T., & Sutherland, G. (2017). Understanding the gap: a Pan-Canadian analysis of prescription drug insurance coverage. Report. Canadian Alliance for Sustainable Health Care. http://innovativemedicines.ca/wp-content/uploads/2017/12/20170712-unders...

Publication types

Grants and funding